Donald Notman - 12 Feb 2026 Form 4 Insider Report for OCULAR THERAPEUTIX, INC (OCUL)

Reporting relationship: Chief Operating Officer
Issuer ticker: OCUL
Reported as of: 12 Feb 2026
Net transaction value: -$103,472
SEC form: 4
Accepted by SEC: 17 Feb 2026, 20:31:05 UTC
Prior SEC filing: 04 Feb 2026
Source filing: View source filing
Reporting owner signature: /s/ Todd Anderman, Attorney-in-Fact for Donald Notman

Key filing fact

Donald Notman filed Form 4 for OCULAR THERAPEUTIX, INC (OCUL) on 17 Feb 2026.

Key facts

This page summarizes Donald Notman's Form 4 filing for OCULAR THERAPEUTIX, INC (OCUL).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 17 Feb 2026, 20:31.

Change

Previous filing in this sequence was filed on 04 Feb 2026.
Current net transaction value: -$103,472.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001718019 Primary reporting owner

Notman Donald

Relationship: Chief Operating Officer
Address: C/O OCULAR THERAPEUTIX, INC., 15 CROSBY DRIVE, BEDFORD
Signature: /s/ Todd Anderman, Attorney-in-Fact for Donald Notman
Signature date: 17 Feb 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

OCUL transaction

Common Stock

Sale

Transaction value: $103,472
Shares: -11,446
Change %: -3%
Price: $9.04
Shares after: 366,356
Date: 12 Feb 2026
Ownership: Direct
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Represents shares of common stock of Ocular Therapeutix, Inc. (the "Corporation") sold, pursuant to a durable automatic sale instruction adopted by the reporting person on May 13, 2022, effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations in connection with the vesting of restricted stock units on February 11, 2026. The sales do not represent a discretionary trade by the reporting person.

Footnote F2

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.9950 to $9.0950, inclusive. The reporting person undertakes to provide to the Corporation, any security holder of the Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.